Pharmacopsychiatry 2007; 40(6): 292-293
DOI: 10.1055/s-2007-992146
Letter

© Georg Thieme Verlag KG Stuttgart · New York

Pregabalin in Benzodiazepine Withdrawal

T. Biermann 1 , S. Bleich 1 , J. Kornhuber 1 , T. Hillemacher 1
  • 1Department of Psychiatry and Psychotherapy, Friedrich-Alexander-University, Erlangen-Nuremberg, Germany
Further Information

Publication History

received 25.06.2007 revised 23.07.2007

accepted 24.07.2007

Publication Date:
21 November 2007 (online)

Introduction

Pregabalin is a well tolerated treatment for generalized and social anxiety (licensed only in European countries and not in the USA), epilepsy as well as neuropathic pain [2].

References

  • 1 Bateson A. Further potential of the GABA receptor in the treatment of insomnia.  Sleep Medicine. 2007;  7 3-9
  • 2 Montgomery SA. Pregabalin for the treatment of generalized anxiety disorder.  Expert Opin Pharmacother. 2006;  7 2139-2154
  • 3 Rupprecht R, Eser D, Zwanzger P, Möller HJ. GABA-A receptors as targets for novel anxiolytic drugs.  World J Biol Psychiatry. 2006;  7 231-237
  • 4 Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery.  Epilepsy Res. 2007;  73 137-150
  • 5 Victorri-Vigneau C, Guerlais M, Jolliet P. Abuse, dependency and withdrawal with gabapentin: a first case report.  Pharmacopsychiatry. 2007;  40 43-44
  • 6 Zullino DF, Khazaal Y, Hattenschwiler J, Borgeat F, Besson J. Anticonvulsant drugs in the treatment of substance withdrawal.  Drugs Today (Barc). 2004;  40 603-619

Correspondence

Dr. med. T. Biermann

Friedrich-Alexander-University of Erlangen-Nuremberg

Department of Psychiatry and Psychotherapy

Schwabachanlage 6-10

91054 Erlangen

Germany

Phone: +49/9131/853 45 97

Fax: +49/9131/853 41 05

Email: teresa.biermann@uk-erlangen.de

    >